Circulating angiotensin peptides levels in Acute Respiratory Distress Syndrome correlate with clinical outcomes: A pilot study
Autor: | Siyu Liu, Kathleen E. Rodgers, Ahmet Baydur, Stan G. Louie, Janice M. Liebler, Isaac Asante, Pranay Parikh, Raju Reddy, Zea Borok |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Male ARDS Critical Care and Emergency Medicine Pulmonology Physiology Enzyme Metabolism Pilot Projects 030204 cardiovascular system & hematology Gastroenterology Biochemistry 0302 clinical medicine Tandem Mass Spectrometry Blood plasma Medicine and Health Sciences Renal Failure Enzyme Chemistry Acute Respiratory Distress Syndrome Chromatography High Pressure Liquid education.field_of_study Respiratory Distress Syndrome Multidisciplinary Receptors Angiotensin biology Middle Aged Body Fluids Enzymes Blood Nephrology Angiotensin-converting enzyme 2 Acute Disease Medicine Female Angiotensin-Converting Enzyme 2 Anatomy Research Article Agonist Adult medicine.medical_specialty medicine.drug_class Death Rates Science Peptidyl-Dipeptidase A Blood Plasma 03 medical and health sciences Respiratory Failure Population Metrics Internal medicine Renin–angiotensin system medicine Humans education Population Biology business.industry Ras Peptide Biology and Life Sciences Proteins Angiotensin-converting enzyme Kidneys Renal System medicine.disease Angiotensin II receptor type 2 030104 developmental biology biology.protein Enzymology Angiotensin I business Peptides Biomarkers |
Zdroj: | PLoS ONE PLoS ONE, Vol 14, Iss 3, p e0213096 (2019) |
ISSN: | 1932-6203 |
Popis: | RationaleWe propose renin angiotensin system (RAS) peptides are critical in wound reparative processes such as in acute respiratory distress syndrome (ARDS). Their role in predicting clinical outcomes in ARDS has been unexplored; thus, we used a targeted metabolomics approach to investigate them as potential predictors of outcomes.MethodsThirty-nine ARDS patients were enrolled within 24 hours of ARDS diagnosis. Plasma RAS peptide levels were quantified at study entry and 24, 48 and 72 hours using a liquid chromatography-mass spectrometry based metabolomics assay. RAS peptide concentrations were compared between survivors and non-survivors, and were correlated with clinical and pulmonary measures.Measurements and main resultsAngiotensin I (Ang-I or A(1-10)) levels were significantly higher in non-survivors at study entry and 72 hours. ARDS survival was associated with lower A(1-10) concentration (OR 0.36, 95% CI 0.18-0.72, p = 0.004) but higher A(1-9) concentration (OR 2.24, 95% CI 1.15-4.39, p = 0.018), a biologically active metabolite of A(1-10) and an agonist of angiotensin II receptor type 2. Survivors had significantly higher median A(1-9)/A(1-10) and A(1-7)/A(1-10) ratios than the non-survivors (p = 0.001). Increased A(1-9)/A(1-10) ratio suggests that angiotensin converting enzyme II (ACE2) activity is higher in patients who survived their ARDS insult while an increase in A(1-7)/A(1-10) ratio suggests that ACE activity is also higher in survivors.ConclusionA(1-10) accumulation and reduced A(1-9) concentration in the non-survivor group suggest that ACE2 activities may be reduced in patients succumbing to ARDS. Plasma levels of both A(1-10) and A(1-9) and their ratio may serve as useful biomarkers for prognosis in ARDS patients. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |